Stem Cell Stock Tracker

Welcome to the stem cell stock tracker page, where we track and catalog up-to-date information on publicly traded companies engaged in stem cell research in the United States and abroad.

Stem cells—the body’s master cells capable of repairing and regenerating damaged tissues—are at the heart of this transformation. From NASDAQ giants like AstraZeneca to innovative players such as Mesoblast, Lineage Cell Therapeutics, and Pluri Inc., publicly traded companies are pioneering therapies that could redefine healthcare.

As of November 2025, the global stem cell therapy market is valued at approximately $18.13 billion and is projected to surge to $54.15 billion by 2034, growing at a robust CAGR of 12.95%. This explosive expansion is fueled by advancements in regenerative medicine, rising demand for treatments targeting chronic diseases like cancer, Parkinson’s, and heart conditions, with clinical trials increasing worldwide.

Disclaimer: Investing in stocks, particularly in the biotechnology and stem cell sectors, involves substantial risks, including the potential for complete loss of principal. Stock prices can be highly volatile due to clinical trial outcomes, regulatory approvals, market conditions, and other factors. This website provides information for educational purposes only and is not financial advice. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Stem Cell Tracker is not affiliated with or endorsed by any company mentioned on this page, and may hold investments in featured securities from time to time. Past performance is no guarantee of future results.